Drug Profile
KL 7016
Alternative Names: KL7016Latest Information Update: 19 Apr 2016
Price :
$50
*
At a glance
- Originator KT&G Life Sciences
- Class Eye disorder therapies
- Mechanism of Action Nicotinamide adenine dinucleotide modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Dry eyes
Most Recent Events
- 19 Apr 2016 No recent reports on development identified - Phase-II for Dry eyes in South Korea (PO)
- 01 Jul 2014 KT&G Life Sciences completes a phase II trial in Dry eyes in South Korea (NCT02092207)
- 01 Oct 2012 Phase-II clinical trials in Dry eyes in South Korea (PO)